CD27及CD56对以硼替佐米为基础治疗的初诊MM患者预后的意义

Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib

目的:探讨CD27及CD56对多发性骨髓瘤(MM)患者预后的指导意义,确立一种简易方便的预后危险评分。方法:选择本院2013年1月1日至2019年1月1日以硼替佐米为基础治疗的初诊MM患者111例,分析患者临床特征与生存期的关系。结果:CD27^(+)CD56^(+)组患者OS长于非CD27^(+)CD56^(+)组(P<0.05)。β2-MG≥5.5 mmol/L、血清钙>2.5 mmol/L及非CD27^(+)CD56^(+)表达是以硼替佐米为基础治疗的MM患者的独立危险因素。结论:以硼替佐米为基础治疗的MM患者中,CD27^(+)CD56^(+)患者预后好于非CD27^(+)CD56^(+)患者。具备过高的β2-MG和血清钙浓度及非CD27^(+)CD56^(+)表达3个危险因素的患者预后极差,需尽早给予临床试验或造血干细胞移植等治疗措施。

Objective:To investigate the significance of CD27 and CD56 in the prognosis of multiple myeloma(MM) patients,and to establish a simple and convenient prognostic risk score.Methods:One hundred and eleven newly diagnosed MM patients treated by bortezomib in Shengjing hospital from January 1,2013 to January 1,2019 were selected,and the relationship between clinical characteristics and survival time of patients was analyzed.Results:The overall survival(OS) of patients in CD27^(+)CD56^(+) group was longer than that of patients in non-CD27^(+)CD56^(+) group(P<0.05).β2-microglobulin≥5.5 mmol/L,serum calcium>2.5 mmol/L and expression of non-CD27^(+)CD56^(+) were the independent risk factors in patients with MM treated by bortezomib.Conclusion:Among patients with MM treated by bortezomib,CD27^(+)CD56^(+) patients show better prognosis than non-CD27^(+)CD56^(+) patients.The prognosis of patients with3 risk factors of β2-MG and serum calcium concentration above the critical value and non-CD27^(+)CD56^(+) expression is very poor,and clinical trials or hematopoietic stem cell transplantation or other treatment measures should be given as soon as possible.